US equities
|
INTC
$64.82
▼-29.60%
AMZN
$238.37
▼-2.22%
MU
$880.80
▼-5.72%
NVDA
$205.43
▼-3.85%
SNDK
$1,167.12
▼-12.25%
GOOGL
$281.88
▼-0.68%
SPCX
$138.21
▼-3.95%
TSLA
$400.29
▼-0.75%
INTC
$64.82
▼-29.60%
AMZN
$238.37
▼-2.22%
MU
$880.80
▼-5.72%
NVDA
$205.43
▼-3.85%
SNDK
$1,167.12
▼-12.25%
GOOGL
$281.88
▼-0.68%
SPCX
$138.21
▼-3.95%
TSLA
$400.29
▼-0.75%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
18.63
-0.60 (-3.12%)
Delayed Quote
Updated: 12:04 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
Sarepta Therapeutics to Present at Upcoming Investor Conferences
October 26, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results
October 22, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting
October 14, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
October 05, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Sarepta Therapeutics (NASDAQ:SRPT) Surges on Q2 Earnings Beat and Narrowed Outlook
↗
August 05, 2026
Via
Chartmill
Topics
Earnings
Sarepta Therapeutics (NASDAQ:SRPT) Q1 2026 Earnings Beat Overshadowed by Revenue Dip
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
September 30, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
September 25, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
September 24, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
↗
September 15, 2026
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic...
Via
MarketBeat
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
September 08, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
August 31, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT
August 24, 2026
From
Kahn Swick & Foti, LLC
Via
Business Wire
Sarepta (SRPT) Q2 2026 Earnings Call Transcript
↗
August 12, 2026
Revenue fell 34% YoY as management narrows guidance and eyes 2027 growth.
Via
The Motley Fool
Topics
Earnings
Intellectual Property
Sarepta Therapeutics Q2 Earnings Call Highlights
↗
August 06, 2026
Sarepta Therapeutics (NASDAQ:SRPT) reported second-quarter 2026 total revenue of $401 million, down 34% from a year earlier, as lower ELEVIDYS sales weighed on results. The company nevertheless posted...
Via
MarketBeat
Topics
Earnings
Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments
August 05, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 29, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer
July 27, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results
July 22, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
2 Beaten-Down Stocks That Still Aren't Worth Buying
↗
July 11, 2026
Your hard-earned money would be better spent elsewhere.
Via
The Motley Fool
Topics
Artificial Intelligence
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®
June 30, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
Via
Investor Brand Network
NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation
June 03, 2026
Via
Investor Brand Network
Topics
Artificial Intelligence
Intellectual Property
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
June 03, 2026
From
BioMedWire
Via
GlobeNewswire
Sarepta Therapeutics to Participate in Upcoming Investor Conferences
June 01, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
My Top 3 Biotech Stocks for May 2026
↗
May 20, 2026
As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies are beginning to stand out from the crowd.
Via
The Motley Fool
Topics
Artificial Intelligence
Intellectual Property
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
May 13, 2026
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta (SRPT) Q1 2026 Earnings Transcript
↗
May 06, 2026
Sarepta (SRPT) Q1 2026 Earnings Transcript
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
36
37
Next >
